Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Company Info
Headquarters
Number of Employees
Revenue (in millions)
Contact Info
Visit Website
Tagline
Overview
Company Services
Site Information
Contributors
Contributions
3D Bioprinting
Lonza and Allevi Collaborate to Advance 3D Bioprinting
PR-M01-20-NI-012
Bispecific Antibody
Challenges of Manufacturing the Expanding Range of Bi/Multispecific Modalities
PAP-Q4-19-CL-022
Agreement
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
PR-M10-19-NI-006
Partnership
Lonza Partners with Vineti Across its Cell and Gene Therapy Manufacturing Network to Optimize 'Vein-to-Vein' Delivery Service
PR-M08-19-NI-008
Growth
Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Business
PR-M07-19-NI-069
Acquisition
Lonza Will Purchase a Sterile Fill-Finish Site from Novartis
PAO-M07-19-NI-012
M&A
Lonza to Acquire Sterile Fill and Finish Facility from Novartis
PR-M07-19-NI-010
Partnership
Alector Opts for Lonza’s Ibex™ Develop to Secure Future Manufacturing for Neurodegeneration Therapies
PR-M05-19-NI-032
DCAT '19
Highly Potent API and Sterile Capabilities Key to DCAT Week ‘19 Company Announcements
PAO-M03-19-NI-024
Biologic Candidates
Addressing Development Challenges for Complex Biologic Drug Candidates
PAP-Q2-18-CL-004
Manufacturing Agreement
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
PR-M05-18-NI-046
Cell Culture Portfolio
Lonza Expands Cell-Culture Portfolio with Quasi Vivo ® System
PR-M02-18-NI-59
Strategic Partnership
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
PR-M02-18-NI-047
Research
Lonza to Present Latest Research into More Physiologically Relevant ADME-Tox Models at the Society of Toxicology Meeting
PR-M02-18-NI-034
